| Apatinib for the treatment of gastric cancer G Roviello, A Ravelli, AI Fiaschi, MR Cappelletti, A Gobbi, C Senti, ... Expert Review of Gastroenterology & Hepatology 10 (8), 887-892, 2016 | 87 | 2016 |
| Breast cancer circulating biomarkers: advantages, drawbacks, and new insights A Ravelli, JM Reuben, F Lanza, S Anfossi, MR Cappelletti, L Zanotti, ... Tumor Biology 36, 6653-6665, 2015 | 51 | 2015 |
| Longitudinal circulating levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC patients treated with sorafenib M Manganelli, I Grossi, M Ferracin, P Guerriero, M Negrini, M Ghidini, ... Biomedicines 9 (7), 813, 2021 | 23 | 2021 |
| Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience M Ghidini, BM Donida, L Totaro, M Ratti, C Pizzo, I Benzoni, D Lomiento, ... Clinical and Translational Oncology 22, 1004-1012, 2020 | 19 | 2020 |
| No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of … G Roviello, L Zanotti, MR Cappelletti, A Gobbi, C Senti, A Bottini, ... Clinical Lung Cancer 17 (5), 334-340, 2016 | 19 | 2016 |
| Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trials G Roviello, MR Cappelletti, L Zanotti, A Gobbi, C Senti, A Bottini, A Ravelli, ... Medicine 95 (43), e4636, 2016 | 15 | 2016 |
| A phase II study of olaparib in breast cancer patients: biological evaluation from a ‘window of opportunity’trial G Roviello, M Milani, A Gobbi, M Dester, MR Cappelletti, G Allevi, ... Future Oncology 12 (19), 2189-2193, 2016 | 12 | 2016 |
| Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer G Bregni, C Vandeputte, A Pretta, C Senti, E Trevisi, E Acedo Reina, ... Acta oncologica 60 (4), 549-553, 2021 | 8 | 2021 |
| Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The … S Camera, T Akin Telli, E Woff, C Vandeputte, P Kehagias, T Guiot, ... Cancers 12 (10), 2752, 2020 | 7 | 2020 |
| Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT) A Ravelli, JM Reuben, F Lanza, S Anfossi, MR Cappelletti, L Zanotti, ... Breast cancer circulating biomarkers: advantages, drawbacks, and new …, 2015 | 7 | 2015 |
| Sex and regorafenib toxicity in refractory colorectal cancer: safety analysis of the RegARd-C trial C Vandeputte, G Bregni, P Gkolfakis, T Guiot, A Pretta, P Kehagias, ... Clinical colorectal cancer 20 (4), 326-333, 2021 | 6 | 2021 |
| Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel G Bregni, T Sticca, S Camera, T Akin Telli, L Craciun, E Trevisi, A Pretta, ... Acta Oncologica 59 (12), 1438-1446, 2020 | 5 | 2020 |
| A phase Ib open-label study to assess the safety and tolerability of everolimus in combination with eribulin in triple-negative breast cancers G Roviello, M Milani, A Gobbi, MR Cappelletti, L Zanotti, C Senti, A Bottini, ... Clinical Breast Cancer 16 (3), e57-e59, 2016 | 5 | 2016 |
| 505TiP REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III … G Bregni, C Senti, EA Reina, P Gkolfakis, L Moretti, A Veron, P Demetter, ... Annals of Oncology 32, S579, 2021 | 3* | 2021 |
| 2326P Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy M Ghidini, JC Hahne, C Senti, G Tomasello, M Ratti, T Heide, O Garrone, ... Annals of Oncology 34, S1188, 2023 | | 2023 |
| Prognostic value of baseline and early changes of circulating cell-free (cf) DNA in the neoadjuvant setting of early stage colon cancer (CC) G Bregni, E Trevisi, C Senti, A Pretta, C Vandeputte, P Kehagias, ... Cancer Research 81 (13_Supplement), 28-28, 2021 | | 2021 |
| Expression of exosomal let-7g in biofluids and outcome in colon cancer patient treated with anti-EGFR therapy JC Hahne, A Lampis, M Ghidini, M Ratti, C Senti, R Passalacqua, ... Cancer Research 81 (13_Supplement), 2373-2373, 2021 | | 2021 |
| Prognostic value of baseline and early changes of circulating-free (cf) and circulating tumor (ct) DNA in the neoadjuvant (NA) setting of early stage colon cancer (CC). G Bregni, C Senti, C Vandeputte, E Acedo Reina, P Gkolfakis, ... Journal of Clinical Oncology 39 (15_suppl), 3600-3600, 2021 | | 2021 |
| 18F-FDG PET scan and liquid biopsy as tools to assess the pace of tumor progression and to predict overall survival (OS) in refractory colorectal cancer (rCRC): The CORIOLAN trial. S Camera, T Akin Telli, E Woff, P Kehagias, T Guiot, G Critchi, G Bregni, ... Journal of Clinical Oncology 38 (15_suppl), e16012-e16012, 2020 | | 2020 |
| Circulating-free DNA analysis from long-term surviving metastatic colorectal cancer patients undergoing surgery for resectable disease M Ghidini, JC Hahne, C Senti, A Lampis, M Ratti, C Pizzo, G Tomasello, ... Annals of Oncology 30, v767, 2019 | | 2019 |
